Collaboration, Option and License Agreement Sample Contracts
COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • April 5th, 2017 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS COLLABORATION, OPTION AND LICENSE AGREEMENT (the “Agreement”) is entered into as of August 8, 2016 (“Effective Date”), by and between ADVERUM BIOTECHNOLOGIES, INC., a Delaware corporation having an address at 1035 O’Brien Drive, Menlo Park, CA 94025 (“Adverum”), and EDITAS MEDICINE, INC., a Delaware corporation having an address at 300 Third Street, Cambridge, MA 02142 (“Editas”). Adverum and Editas may be referred to herein individually as a “Party” and collectively as the “Parties.”
Standard Contracts
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. COLLABORATION,...Collaboration, Option and License Agreement • May 8th, 2024 • Merus N.V. • Pharmaceutical preparations • New York
This Collaboration, Option and License Agreement (the “Agreement”), effective as of March 5, 2024 (the “Effective Date”), is made by and between:
SECOND AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • August 8th, 2018 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • Delaware
This Second Amendment (“Second Amendment”) is entered into as of June 5, 2018 (the “Second Amendment Effective Date”), by and between Adverum Biotechnologies, Inc., a Delaware corporation having an address at 1035 O’Brien Drive, Menlo Park, CA 94025 (“Adverum”), and Editas Medicine, Inc., a Delaware corporation having an address at 11 Hurley St., Cambridge, MA 02141 (“Editas”), and amends that certain Collaboration, Option and License Agreement, dated August 8, 2016, by and between Adverum and Editas, as amended by that certain Amendment to Collaboration, Option and License Agreement, dated January 25, 2018 (the “Agreement”). Adverum and Editas may be referred to herein individually as a “Party” and collectively as the “Parties.”
FIRST AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • October 6th, 2022 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • California
This First Amendment to Collaboration, Option and License Agreement (this “First Amendment”), dated August 13, 2019 (the “First Amendment Effective Date”), is by and between Nurix Therapeutics, Inc., a Delaware corporation (“Nurix”) and Gilead Sciences, Inc., a Delaware corporation (“Gilead”).
COLLABORATION, OPTION AND LICENSE AGREEMENT BY AND BETWEEN JANSSEN PHARMACEUTICALS, INC., MEIRAGTX UK II LIMITED AND MEIRAGTX HOLDINGS PLCCollaboration, Option and License Agreement • March 26th, 2019 • MeiraGTx Holdings PLC • Biological products, (no disgnostic substances) • New York
This Collaboration, Option and License Agreement (this “Agreement”) is made as of January 30, 2019 (the “Execution Date”), by and between Janssen Pharmaceuticals, Inc., a Pennsylvania corporation located at 1125 Trenton-Harbourton Road, Titusville, NJ 08560, United States of America (“Janssen”), on the one hand, and MeiraGTx UK II Limited, a company organized and existing under the laws of England, located at 25 Provost Street, London N1 7NH, United Kingdom and MeiraGTx Holdings plc, a Cayman Islands corporation located at 430 East 29th Street, 10th Floor, New York, NY 10016, United States of America (MeiraGTx UK II Limited and MeiraGTx Holdings plc, individually or collectively, “MeiraGTx”), on the other hand. Janssen and MeiraGTx are each referred to individually as a “Party” and together as the “Parties.”
AND LICENSE AGREEMENTCollaboration, Option and License Agreement • November 19th, 2021 • Exicure, Inc. • Pharmaceutical preparations • New York
[***] - Certain portions of the exhibit have been omitted pursuant to Rule 601(b)(10) because it is both (i) not material to investors and (ii) information that the Company treats as private or confidential.
COLLABORATION, OPTION AND LICENSE AGREEMENT between EXICURE, INC. and ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED November 13, 2019Collaboration, Option and License Agreement • March 10th, 2020 • Exicure, Inc. • Pharmaceutical preparations • New York
This COLLABORATION, OPTION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of November 13, 2019 (the “Effective Date”), by and between EXICURE, INC., a Delaware corporation with a place of business at 8045 Lamon Avenue, Suite 410, Skokie, IL 60077 (“Exicure”), and ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED, a private company limited by shares, with a place of business at Clonshaugh Business & Technology Park, Dublin 17, D17 E400, Ireland (“Allergan”). In this Agreement, Allergan and Exicure are collectively referred to as the “Parties” and each individually as a “Party”.
CERTAIN INFORMATION (INDICATED BY ASTERISKS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED COLLABORATION, OPTION AND LICENSE AGREEMENT by and between...Collaboration, Option and License Agreement • March 1st, 2021 • Zogenix, Inc. • Pharmaceutical preparations • New York
This COLLABORATION, OPTION, AND LICENSE AGREEMENT (the “Agreement”) is entered into and made effective as of December 3, 2020 (the “Effective Date”) by and between Tevard Biosciences, Inc., a Delaware corporation (“Tevard”); and Zogenix, Inc., a Delaware corporation (“Zogenix”). Tevard and Zogenix are each referred to herein by name or as a “Party” or, collectively, as “Parties.”
COLLABORATION, OPTION, AND LICENSE AGREEMENTCollaboration, Option, and License Agreement • August 7th, 2019 • Vir Biotechnology, Inc. • Biological products, (no disgnostic substances) • New York
This COLLABORATION, OPTION, AND LICENSE AGREEMENT (this “Agreement”) is made as of 23 May, 2018 (the “Execution Date), and effective as of the Effective Date (as defined herein) by and between VIR BIOTECHNOLOGY, INC., a Delaware corporation, having a place of business at 499 Illinois Street, San Francisco, California 94158, United States of America (“Vir”), BIIG THERAPEUTICS LIMITED, DBA BRII BIOSCIENCES LIMITED, a corporation organized under the laws of the Cayman Islands, having a registered office at Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1—1205 Cayman Islands (“Parent”), and BRII BIOSCIENCES OFFSHORE LIMITED a corporation to be established by Parent in accordance with Section 17.1 of this Agreement and organized under the laws of the Cayman Islands, having a registered office at Vistra (Cayman) Limited, P. O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1—1205 Cayman Islands (“Brii Bi
SECOND AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • October 6th, 2022 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • California
This Second Amendment to Collaboration, Option and License Agreement (this “Second Amendment”), dated September 9, 2022 (the “Second Amendment Effective Date”), is by and between Nurix Therapeutics, Inc., a Delaware corporation (“Nurix”) and Gilead Sciences, Inc., a Delaware corporation (“Gilead”).
ContractCollaboration, Option and License Agreement • July 2nd, 2020 • Nurix Therapeutics, Inc. • Pharmaceutical preparations • California
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.
Collaboration, Option and License AgreementCollaboration, Option and License Agreement • April 23rd, 2021 • Vividion Therapeutics, Inc. • Pharmaceutical preparations • New York
WHEREAS, Vividion has expertise in proteome wide small molecule discovery approaches building on a proprietary library of small molecules designed to bind covalently in a selective manner to target proteins;
Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION, OPTION...Collaboration, Option and License Agreement • November 7th, 2022 • Mersana Therapeutics, Inc. • Pharmaceutical preparations • New York
Certain identified information has been excluded from the exhibit because it is both (i) not material and Double asterisks denote omissions. AMENDMENT to Collaboration, Option and license AgreementCollaboration, Option and License Agreement • May 14th, 2020 • Ocular Therapeutix, Inc • Pharmaceutical preparations
This Amendment to the Collaboration, Option and License Agreement (the “Amendment”) is entered into and made effective as of May 8, 2020 (the “Amendment Effective Date”) and amends that certain Collaboration, Option and License Agreement dated October 10, 2016 (the “Agreement”), by and between Ocular Therapeutix, Inc., a corporation organized and existing under the laws of the State of Delaware with offices at 36 Crosby Drive, Suite 101, Bedford, Massachusetts 01730 (“Collaborator”) and Regeneron Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of New York with offices at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (“Regeneron”). Collaborator and Regeneron are referred to herein individually as a “Party” and collectively as the “Parties”.
Amendment No. 2 to Collaboration, Option and License AgreementCollaboration, Option and License Agreement • May 10th, 2022 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations
This Amendment No. 2 (the “Amendment No. 2”) to the Collaboration, Option and License Agreement entered into as of June 15, 2020 between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (“GSK”), a company registered in England and Wales (registered number 11721880), and IDEAYA Biosciences, Inc., (“IDEAYA”) a Delaware corporation having an office at 7000 Shoreline Court, Suite 350, South San Francisco, CA 94080, as amended by the Amendment No. 1 effective as of October 23, 2020 (the “Agreement”) is effective as of January 31, 2022 (“Amendment No. 2 Effective Date”). GSK and IDEAYA are sometimes referred to individually as a “Party” and collectively as the “Parties.”
COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • August 27th, 2021 • iBio, Inc. • Pharmaceutical preparations • Delaware
This Collaboration, Option and License Agreement (together with all Exhibits and Schedules attached hereto, this “Agreement”) is made as of August 23, 2021 (the “Effective Date”), by and between RubrYc Therapeutics, Inc., a corporation organized and existing under the laws of Delaware, located at 733 Industrial Road, San Carlos, CA 94070 (“RubrYc”), and iBio, Inc., a corporation organized under the laws of the State of Texas, located at 8800 HSC Pkwy, Bryan, TX 77807 (“iBio”). RubrYc and iBio are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENTCollaboration, Option and License Agreement • March 6th, 2018 • Adverum Biotechnologies, Inc. • Biological products, (no disgnostic substances) • Delaware
This Amendment (“Amendment”) is entered into as of January 25, 2018 (the “Amendment Effective Date”), by and between Adverum Biotechnologies, Inc., a Delaware corporation having an address at 1035 O’Brien Drive, Menlo Park, CA 94025 (“Adverum”), and Editas Medicine, Inc., a Delaware corporation having an address at 11 Hurley St., Cambridge, MA 02141 (“Editas”) and amends that certain Collaboration, Option and License Agreement, dated August 8, 2016, by and between Adverum and Editas (the “Agreement”). Adverum and Editas may be referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATION, OPTION AND LICENSE AGREEMENT BetweenCollaboration, Option and License Agreement • August 12th, 2020 • IDEAYA Biosciences, Inc. • Pharmaceutical preparations • New York
This Collaboration, Option and License Agreement (the “Agreement”) is made and entered into as of June 15, 2020 (“Execution Date”) and is effective as of the Effective Date (as defined below), between GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 4) LIMITED (“GSK”), and IDEAYA Biosciences, Inc., a Delaware corporation having an office at 7000 Shoreline Court, Suite 350, South San Francisco, CA 94080 (“IDEAYA”). GSK and IDEAYA are sometimes referred to individually as a “Party” and collectively as the “Parties.”
ContractCollaboration, Option and License Agreement • December 14th, 2022 • Exicure, Inc. • Pharmaceutical preparations
Allergan Pharmaceuticals International Limited Clonshaugh Business & Technology Park Dublin 17 D17 E400, Ireland www.allergan.com
